Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Get Free Report) EVP Ourania Tatsis sold 1,500 shares of the business's stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $499.99, for a total transaction of $749,985.00. Following the sale, the executive vice president directly owned 46,132 shares of the company's stock, valued at approximately $23,065,538.68. The trade was a 3.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Ourania Tatsis also recently made the following trade(s):
- On Wednesday, February 11th, Ourania Tatsis sold 466 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $460.43, for a total transaction of $214,560.38.
- On Wednesday, January 7th, Ourania Tatsis sold 4,500 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $474.99, for a total value of $2,137,455.00.
Vertex Pharmaceuticals Stock Down 1.5%
Shares of Vertex Pharmaceuticals stock opened at $470.31 on Thursday. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $519.68. The business has a 50 day moving average price of $462.29 and a 200-day moving average price of $427.83. The company has a market cap of $119.47 billion, a PE ratio of 30.68 and a beta of 0.30.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.05 by ($0.02). The company had revenue of $3.19 billion for the quarter, compared to analysts' expectations of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The firm's quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the firm earned $3.98 EPS. As a group, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.
Hedge Funds Weigh In On Vertex Pharmaceuticals
Large investors have recently modified their holdings of the business. Brighton Jones LLC grew its stake in Vertex Pharmaceuticals by 15.0% in the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company's stock valued at $1,783,000 after buying an additional 579 shares in the last quarter. Stratos Wealth Advisors LLC boosted its holdings in shares of Vertex Pharmaceuticals by 6.3% in the second quarter. Stratos Wealth Advisors LLC now owns 454 shares of the pharmaceutical company's stock worth $202,000 after acquiring an additional 27 shares during the period. Chicago Partners Investment Group LLC grew its position in shares of Vertex Pharmaceuticals by 18.6% in the second quarter. Chicago Partners Investment Group LLC now owns 1,124 shares of the pharmaceutical company's stock valued at $536,000 after purchasing an additional 176 shares in the last quarter. Stephens Inc. AR raised its stake in shares of Vertex Pharmaceuticals by 2.3% during the 2nd quarter. Stephens Inc. AR now owns 3,392 shares of the pharmaceutical company's stock valued at $1,510,000 after purchasing an additional 77 shares during the period. Finally, Drive Wealth Management LLC lifted its holdings in Vertex Pharmaceuticals by 16.4% during the 2nd quarter. Drive Wealth Management LLC now owns 1,249 shares of the pharmaceutical company's stock worth $556,000 after purchasing an additional 176 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on the stock. Canaccord Genuity Group boosted their price target on shares of Vertex Pharmaceuticals from $411.00 to $441.00 and gave the stock a "hold" rating in a report on Tuesday. Cantor Fitzgerald restated an "overweight" rating and issued a $590.00 price objective on shares of Vertex Pharmaceuticals in a research note on Friday, February 13th. Scotiabank lifted their target price on Vertex Pharmaceuticals from $495.00 to $558.00 and gave the stock an "outperform" rating in a research note on Friday, February 13th. Barclays increased their price target on shares of Vertex Pharmaceuticals from $606.00 to $607.00 and gave the company an "overweight" rating in a research report on Tuesday. Finally, Weiss Ratings raised shares of Vertex Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, February 4th. Twenty-two research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $542.00.
Check Out Our Latest Report on Vertex Pharmaceuticals
Vertex Pharmaceuticals Company Profile
(
Get Free Report)
Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.
Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
